Showing results (61-70 of 72) with videos related to

Sort By:
Pageof 8
In Vivo (Athens, Greece)|March 7, 2023
Preferences Regarding Breast Surgery Omission Among Patients With Breast Cancer Who Receive Neoadjuvant ChemotherapyKaho Nakamura, Makoto Ishitobi, Chiya Oshiro, et al.
Cancer Science|October 20, 2012
Immunotherapeutic benefit of α-interferon (IFNα) in survivin2B-derived peptide vaccination for advanced pancreatic cancer patientsHidekazu Kameshima, Tetsuhiro Tsuruma, Goro Kutomi, et al.
Molecular and Clinical Oncology|April 24, 2023
Positional advantages of supine MRI for diagnosis prior to breast‑conserving surgeryGoro Kutomi, Hiroaki Shima, Daisuke Kyuno, et al.
Cancer Immunology, Immunotherapy : CII|August 3, 2018
Case report: Long-term survival of a pancreatic cancer patient immunized with an SVN-2B peptide vaccineHiroaki Shima, Goro Kutomi, Fukino Satomi, et al.
Cancer Science|November 22, 2023
Eribulin is an immune potentiator in breast cancer that upregulates human leukocyte antigen class I expression via the induction of NOD-like receptor family CARD domain-containing 5Asaka Wada, Yoshihiko Hirohashi, Goro Kutomi, et al.
Surgery Today|February 5, 2015
Trials of vaccines for pancreatic ductal adenocarcinoma: Is there any hope of an improved prognosis?Toru Mizuguchi, Toshihiko Torigoe, Fukino Satomi, et al.
Breast Cancer (Tokyo, Japan)|October 29, 2020
Comparing the extent of breast cancer tumors through contrast-enhanced ultrasound vs B-mode, opposed with pathology: evergreen studyHiroaki Shima, Toshitaka Okuno, Takashi Nakamura, et al.
Cancer Science|June 18, 2019
Immunohistological analysis of pancreatic carcinoma after vaccination with survivin 2B peptide: Analysis of an autopsy seriesTerufumi Kubo, Giichiro Tsurita, Yoshihiko Hirohashi, et al.
The Lancet. Oncology|June 20, 2025
Overall efficacy and safety of olanzapine 5 mg added to triplet antiemetics for an anthracycline-containing regimen in patients with breast cancer: a phase 3, double-blind, randomised, placebo-controlled trialMitsue Saito, Hirotoshi Iihara, Mototsugu Shimokawa, et al.
Cancer Science|June 21, 2019
Randomized phase II trial of survivin 2B peptide vaccination for patients with HLA-A24-positive pancreatic adenocarcinomaHiroaki Shima, Giichiro Tsurita, Satoshi Wada, et al.
Pageof 8